[ intro ]
DNA as the Foundation of Precision Health
Biostate's whole exome sequencing platform delivers high coverage uniformity, minimal zero-coverage regions, and exceptional reproducibility, enabling accurate detection of disease-related genetic variants across all sample types.
[ overview ]
Optimized Chemistry Delivers Superior Performance
Exceptional On-Target Performance and Coverage Uniformity
While most WES providers guarantee raw sequencing output, true value depends on data quality.
Biostate's optimized workflow achieves rapid coverage convergence, with >95% of bases covered with >30X (mean = 100X), significantly outperforming leading competitors.
Consistent Performance Across Challenging Sample Types
Biostate's optimized workflow demonstrates exceptional performance across key metrics, overcoming the coverage uniformity and duplication challenges that undermine variant detection in standard WES workflows.
FFPE Tissue (Single 4-micron Slide)
Biostate achieves ~140X mean target coverage at 40M reads from FFPE samples, despite severe degradation.
This performance supports reliable somatic variant detection even from challenging clinical materials.
Dried Blood Spot (Half-Circle)
A single half-circle dried blood spot yields ~140X mean target coverage, demonstrating consistent performance even with limited DNA input.
Benchmark Genomic DNA
Benchmark genomic DNA processed through the same workflow also reaches ~140X coverage, confirming strong chemistry performance across both high-quality and compromised input types.
MARE — Multiplexed Amplification to Rescue Enrichment
/ about /
MARE is a targeted enrichment technology engineered to rescue difficult genomic regions that standard WES consistently misses—especially exons with extreme GC content.
≈260% median target coverage, vs. ~30% (Competitor A) and <10% (Competitor B)
Maintains >150% normalized coverage on challenging exons such as RALGAPA1 exon 25
Fully customizable panels for clinically relevant or high-value gene sets
/data /
Coverage Rescue in Difficult Genomic Regions
01. MARE boosts coverage nearly 10×
With MARE, difficult loci reach ~270% normalized coverage—dramatically higher than standard workflows.
02. Standard WES fails in these regions
Without MARE, coverage drops to ~30%, leaving critical diagnostic regions insufficiently captured.
03. MARE significantly outperforms competitors
Competitor A achieves <10% coverage, while MARE consistently delivers full and reliable target enrichment.
/ data /
MARE Maintains Coverage in GC-Rich Exons
In challenging high-GC exons like RALGAPA1 exon 25, MARE preserves over 10× higher coverage than competing methods, securing data others can't capture.
MARE Sustains High Coverage
MARE maintains >150% normalized coverage across the difficult RALGAPA1 exon 25, demonstrating stable enrichment in GC-rich regions.
Competitors Fail in Critical Exons
Both standard WES and other commercial kits drop below 15% coverage, leaving essential diagnostic loci undetected.
Reliable Detection Where It Matters Most
MARE ensures uniform signal in even the hardest-to-capture regions—providing complete visibility for precision diagnostics.
